AGEN
$3.99
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally.
Intraday
Recent News
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus: Q4 Earnings Snapshot
LEXINGTON, Mass. AP) — Agenus Inc. AGEN) on Monday reported a loss of $10.6 million in its fourth quarter.
CervoMed Inc. (CRVO) Reports Q4 Loss, Lags Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -10.93% and -98.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC
Agenus Inc. (NASDAQ:AGEN) is one of the most undervalued penny stocks to buy right now. On February 19, Agenus presented new translational and clinical biomarker data from its Phase 1b C-800-01 trial, focusing on the combination of botensilimab/BOT and balstilimab/BAL. The study highlighted the therapy’s effectiveness in immunologically cold tumors, such as microsatellite-stable metastatic colorectal […]
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch
Agenus (NASDAQ:AGEN) used its first 2026 stakeholder webcast to outline operational and clinical priorities tied to its botensilimab/balstilimab (BOT/BAL) immunotherapy program, highlighting a recently closed manufacturing collaboration with Zydus Lifesciences, the expansion of France’s reimbursed e